| abstract |
The present invention also relates to a pharmaceutical composition comprising a free, solvated, pharmaceutically acceptable and / or substantially pure form of a particular substituted heterocyclic fused gamma-carboline, a prodrug thereof, a pharmaceutical composition thereof, and a 5-HT 2A receptor , Serotonin transporter (SERT) and / or pathology associated with the dopamine D 1 / D 2 receptor signaling pathway, and / or methods of use in the treatment of residual symptoms. |